肿瘤化疗药物使用指南和规范

2025-10-23 999+ 326KB 192 页海报

肿瘤化疗药物使用指南与规范

目录
第一章  抗肿瘤药物临床应用的基本原则                                     ............................   1  
一、权衡利弊     最大获益           
二、目的明确     治疗有序           
三、医患沟通     知情同意           
四、治疗适度     规范合理           
五、熟知病情     因人而异           
六、不良反应     谨慎处理           
七、临床试验     积极鼓励           
第二章  抗肿瘤药物临床应用的管理                                           ..................................   3  
一、抗肿瘤药物的管理           
二、监督检查           
一、细胞毒类药物           
二、激素类药物            
三、肿瘤分子靶向与生物治疗            
四、肿瘤治疗辅助药物            
第三章  各类肿瘤的治疗原则                                                 ........................................   57   
一、头颈部恶性肿瘤            
二、胸部肿瘤            
三、消化系统肿瘤            
四、乳腺癌            
五、泌尿系统、男生殖系统肿瘤            

六、妇科肿瘤   

七、血液淋巴系统肿瘤   

八、颅脑肿瘤   

九、原发恶性骨与软组织肿瘤   

第四章呕吐的分级与治疗 ......................................... 160

文档加载中……请稍候！
如果长时间未打开，您也可以点击刷新试试。

下载文档到电脑，查找使用更方便

立即下载

摘要：

《肿瘤化疗药物使用指南与规范》摘要本书系统阐述了肿瘤化疗药物的应用原则、管理规范及各类药物特性。首先强调了抗肿瘤药物临床应用的基本原则：力求患者从抗癌治疗中最大获益权衡利弊规避风险；明确治疗目标有序治疗；医患充分沟通达成共识；规范合理用药避免过度或不足；制定个体化方案因人而异；谨慎处理不良反应有救治预案；鼓励临床试验改善患者生活质量。其次介绍了抗肿瘤药物临床应用的管理包括分级管理（特殊管理药物、一般管理药物、临床试验用药物）、使用管理（药品调配、用药复核、渗漏处理、安全用药、化疗后恶心呕吐处理、化疗期间不良反应监测）、配置管理（制定防护措施与操作规程建立静脉用药调配中心）及人员资质管理。最后针对各类抗肿瘤药物详细说明了其适应证与注意事项包括细胞毒类药物（作用于DNA化学结构的药物、影响核酸合成的药物、作用于核酸转录的药物、作用于DNA复制的拓扑异构酶抑制剂、主要作用于有丝分裂M期干扰微管蛋白合成的药物）等。

展开>> 收起<<

肿瘤化疗药物使用指南和规范.doc

共192页,预览58页

还剩页未读，继续阅读